Legal & General Group
RPRX icon

Legal & General Group’s Royalty Pharma RPRX Stock Holding History

Legal & General Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213M Buy
3,800,504
+437,632
+13% +$22.8M 0.04% 344
2026
Q1 		$161M Buy
3,362,872
+274,774
+9% +$12M 0.04% 403
2025
Q4 		$119M Buy
3,088,098
+265,532
+9% +$10.1M 0.03% 475
2025
Q3 		$99.6M Buy
2,822,566
+103,473
+4% +$3.75M 0.02% 521
2025
Q2 		$98M Sell
2,719,093
-91,787
-3% -$3.04M 0.02% 519
2025
Q1 		$87.5M Buy
2,810,880
+176,998
+7% +$5.61M 0.02% 531
2024
Q4 		$67.2M Buy
2,633,882
+46,030
+2% +$1.22M 0.02% 571
2024
Q3 		$73.2M Buy
2,587,852
+27,423
+1% +$760K 0.02% 573
2024
Q2 		$67.5M Buy
2,560,429
+191,625
+8% +$5.31M 0.02% 570
2024
Q1 		$71.9M Sell
2,368,804
-5,247
-0.2% -$155K 0.02% 550
2023
Q4 		$66.7M Sell
2,374,051
-172,587
-7% -$4.74M 0.02% 562
2023
Q3 		$69.1M Buy
2,546,638
+132,008
+5% +$3.92M 0.02% 546
2023
Q2 		$74.2M Buy
2,414,630
+161,230
+7% +$5.46M 0.02% 549
2023
Q1 		$81.2M Buy
2,253,400
+14,464
+0.6% +$536K 0.03% 523
2022
Q4 		$88.5M Sell
2,238,936
-38,661
-2% -$1.61M 0.03% 488
2022
Q3 		$91.5M Buy
2,277,597
+44,302
+2% +$1.89M 0.04% 476
2022
Q2 		$93.9M Buy
2,233,295
+108,455
+5% +$4.45M 0.03% 499
2022
Q1 		$82.8M Buy
2,124,840
+282,324
+15% +$11.1M 0.03% 579
2021
Q4 		$73.4M Buy
1,842,516
+347,486
+23% +$13.5M 0.02% 604
2021
Q3 		$54M Buy
1,495,030
+23,793
+2% +$925K 0.02% 662
2021
Q2 		$60.3M Buy
1,471,237
+68,665
+5% +$2.92M 0.02% 652
2021
Q1 		$61.2M Buy
1,402,572
+928,993
+196% +$44M 0.02% 622
2020
Q4 		$23.7M Buy
473,579
+447,246
+1,698% +$19M 0.01% 802
2020
Q3 		$1.11M Sell
26,333
-40,019
-60% -$1.72M ﹤0.01% 1993
2020
Q2 		$3.22M Buy
+66,352
New +$3.28M ﹤0.01% 1517

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legal & General Group's RPRX Position: Q2 2026 in Review

Legal & General Group increased its Royalty Pharma (RPRX) stake by 13% in Q2 2026, buying an estimated $22.8M and bringing the position to 3,800,504 shares worth $213M. The position accounts for 0.04% of the portfolio, ranked #344.

Legal & General Group first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Legal & General Group held 3,800,504 shares of Royalty Pharma worth $213M as of Q2 2026.
  • Legal & General Group bought 437,632 Royalty Pharma shares in Q2 2026, an estimated $22.8M.
  • Royalty Pharma made up 0.04% of Legal & General Group's portfolio in Q2 2026, its #344 holding.
  • Legal & General Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.